Uterine myoma is the most common pelvic tumor in women, and its prevalence rate is 40-50% in women of childbearing age.
Materials and Methods
A retrospective study was performed among the women who visited the menopausal clinic in a university hospital from April 2008 to September 2012; subjects were menopausal women in whom an asymptomatic uterine myoma had been identified by ultrasound before starting HRT.
Postmenopause was defined as amenorrhea for longer than a year or serum follicle stimulating hormone level higher than 40 IU/L. The location of uterine myoma in this study was not limited, but the maximum diameter of uterine myoma was over 2 cm, and the number of uterine myoma 
Results
The study included 38 menopausal women. The number of members of the case with HRT was 32, and the control group without HRT was 6. All 32 cases took an EPT. The case was compared by estrogen taking methods.
The numbers in the case with oral estrogen was 22, There were no significant differences among groups.
The mean age was 55.5 ± 4.9, the age for menarche was 15.6 ± 1.7, the age for menopause was 51.8 ± 3.4, and the postmenopausal period was 3.9 ± 3.6 years. There were also no differences between the oral estrogen and the transdermal estrogen groups ( Table 1 ).
The volume increase was not statistically significant compared to the baseline value between the case with hormone therapy and the control groups. And also there were no differences in the size of uterine myoma on baseline to 6 months, 6 months to 12 months, or baseline to 12 months. In addition, there were no differences in the change of the size of uterine myoma according to the prescription method of estrogen, or the progestogen protocol (Table 2 ).
However, there was a significant difference in the change of size of uterine myoma between baseline and 6 months in the oral estrogen and the transdermal estrogen groups (Table 3 ).
The number of cases with a significant change in the size of uterine myoma between baseline and 12 months was 9
(28.1%) (Table 4A ). In 11 cases, the size of uterine myoma had significantly increased at 6 months; however, the size was unchanged or decreased after 6 months in 10 patients.
Oral estrogen group in which the size of uterine myoma had increased after 6 months, was no change or decrease in size after 12 months (Table 4B , 4C, 4D). The size of uterine myoma continued to increase in the 1 remaining patient who Table 1 . Baseline characteristics of the study patients
Estrogen-progestogen therapy (n = 26)
Oral estrogen (n = 22)
Parenteral estrogen (n = 10) 
Discussion
Little has been published referring to the effect of HRT on uterine myomas in postmenopausal women. However, it is assumed that uterine myoma is strongly related with the physiological changes of ovarian hormone in the blood because uterine myoma has not been reported in women who have not started menarche, and the size of uterine myoma decreases after menopause. 5 The presence of oestrogen and progesterone receptors in fibromatous tissue has now been confirmed by several studies. It is well known that uterine myoma occurrence and growth is dependent on estrogen. 16 Furthermore, the role of progesterone in the proliferation of uterine myoma has been proposed. The effect of estrogen and progesterone on the occurrence and growth of uterine myoma has been reported to be strongly related with the increase of hormone receptors on uterine myoma tissue.
17~19
The size of uterine myoma decreases after menopause, which is thought to be associated with decreasing levels of estrogen and progesterone in the blood. However, the effect of exogenous hormone on uterine myoma in menopausal women has not been definitively concluded. In this study, there was no significant change in the size on uterine myoma by HRT in menopausal women. In addition, there were no differences according to the prescription methods of estrogen and progestogen protocols. In this study, similar protocols of progestogen were used in the oral estrogen and the transdermal estrogen groups;
nevertheless, there was a significant difference in the size of uterine myoma between baseline and 6 months. Remarkably, the results of the present study are uneven and inconsistent, Attentive size follow-up are important in case with uterine myoma during HRT. Colacurci et al. 8 reported that followup ultrasounds performed once every 3 months are helpful to evaluate changes in the size of uterine myoma. And also, the decrease in the resistance of the uterine artery by the Doppler test is related to an increase in the size of uterine myoma after HRT.
Continuous growing uterine myoma causes doctors and patients anxious during HRT because it is difficult to diagnose uterine myoma and uterine sarcoma differently with only diagnostic radiologic studies including ultrasound.
Uterine sarcoma is a rare malignant tumor which occurs as less than 1% of all malignant tumors, and has poor prognosis. 22 Less than 0.5% patients who were diagnosed with uterine myoma before surgery are found as the sarcoma after surgery. 23 In addition, it is unknown whether uterine sarcoma originates from uterine myoma or uterine muscle cells. Besides, there is no evidence that exogenous estrogen increases the incidence rate of uterine sarcoma.
If the size of uterine myoma increases continuously, medications should be changed, or medications should be discontinued temporarily and then check up the change of size.
This study has some limitations. It is a retrospective study that depends on medical records, and the number of the subjects is small. Another limitation is that the ultrasounds were performed by different radiologists. In addition, various hormone medications could have interactions with one another. Therefore, various prospective randomized studies are needed with a sufficient number of subjects.
In conclusion, HRT did not affect the size of uterine myoma significantly in menopausal women. There were no differences by used methods of estrogen or progestogen protocols. Our results appear to encourage the use of HRT in menopausal women with uterine myomas. However, attentive follow-up is needed in case of a continuous increase in the size of uterine myoma.
